BioLineRx Ltd. (BLRX) stock
BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.15+0.03 (+2.68%)
Close on Nov 18, 2026Market cap $5.00MP/E –Yield –
BioLineRx gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was $950.00K, down 95.2% from the year before. The highest annual figure on record is $19.68M in fiscal 2024.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $950.00K | -95.2% |
| FY2024 | Dec 31, 2024 | $19.68M | +1675.9% |
| FY2023 | Dec 31, 2023 | $1.11M | – |
| FY2022 | Dec 31, 2022 | $0 | – |
| FY2021 | Dec 31, 2021 | $0 | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $235.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $232.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $4.50M | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
See a number that looks wrong?